Combination of BA-210 and digestion of the glial scar in chronic spinal cord injury

描述（由申请人提供）：BA-210是一种靶向Rho的研究药物，Rho是一种对控制脊髓损伤后轴突再生和修复至关重要的细胞内GT酶。BA-210已完成治疗急性脊髓损伤的I/IIa期临床试验 48例患者。BA-210不仅安全且耐受性良好，而且颈椎SCI患者的手臂和手部运动恢复非常有希望。虽然目前的发展是治疗急性脊髓损伤，BA-210有可能改善慢性SCI患者的预后，特别是如果与其他疗法联合使用。治疗慢性SCI的一个障碍是 脊髓损伤后形成和残留的胶质瘢痕。目前市场上的几种药物具有消化胶质瘢痕的潜力，可以重新用于SCI。将BA-210与重新用途的药物相结合将加速临床试验和批准的监管路径。该SBIR项目的总体目标是研究BA-210与两种消化胶质瘢痕的药物之一联合使用作为慢性SCI的治疗。

DESCRIPTION (provided by applicant): BA-210 is an investigational drug that targets Rho, an intracellular GTPase important for controlling axon regeneration and repair after spinal cord injury. BA-210 has completed a Phase I/IIa clinical trial for treatment of acute spinal cord injury in 48 patients. Not only was BA-210 safe and well tolerated, but patients with cervical SCI showed very promising recovery of arm and hand movements. While current development is to treat acute spinal cord injury, BA-210 has potential to improve outcome in patients with chronic SCI, especially if used in combination with other therapies. One barrier to treating chronic SCI is the glial scar that develops and remains after SCI. Several drugs currently on the market have the potential to digest the glial scar and could be repurposed for SCI. Combining BA-210 with a repurposed drug will accelerate the regulatory path to clinical trials and approval. The overall goal of this SBIR project is to investigate the use of BA-210 in combination with one of two drugs that digest the glial scar as a treatment for chronic SCI.